IPR Appeal Dismissed After Biosimilar Development Discontinued
By Jihong Lou, Ph.D. and Cary Miller, Ph.D. Article III of the Constitution imposes a “case or controversy” limitation on the jurisdiction of federal courts: an actual case or controversy must exist between the parties at all stages of the federal court proceedings,...
read more
A New Game: Better PTAB Defense Litigation Strategies
Patent Trial and Appeal Board, or PTAB, defense litigation strategies continue to evolve. In a recent Law360 article, Jones Day Intellectual Property lawyers Dave Cochran, Mike Hendershot, and Matt Johnson explained why previous assumptions and strategies pertaining...
read more
Amended Claims In IPRs Must Clear Higher Hurdle Than Original Claims
By John Marlott An IPR of issued patent claims is statutorily limited to prior art challenges based on patents and printed publications under § 102 (novelty) or § 103 (obviousness). The PTAB may not institute an IPR of existing patent claims on other unpatentability...
read more
Court of Federal Claims: Patents Are “Public Franchises, Not Private Property”
By Emily Tait Since April 2018 when the U.S. Supreme Court handed down its Oil States decision, patent owners have made various arguments addressing issues that were not resolved in that case. One such example is Christy, Inc. v. United States, Case No. 1:18-cv-00657...
read more
Joined Parties Have Statutory Standing To Appeal
By: Jennifer L. Swize and Daniel Kazhdan In Friday’s decision in Mylan Pharmaceuticals Inc. v. Research Corp. Technologies, Inc., No. 17-2088 (Fed. Cir. Feb. 1, 2019), the Federal Circuit held that a time-barred petitioner that is joined into a case has an independent...
read more